Acumen posts Q1 net loss $20.7M; Phase 2 AD topline results expected late 2026

Acumen Pharmaceuticals, Inc.

• Cash and marketable securities totaled $128.4M as of Mar 31, 2026; funded into early 2027.
• Net loss $20.7M for Q1 2026 vs $28.8M in Q1 2025; R&D expense fell to $16.5M from $25.3M.
• Topline results from Phase 2 ALTITUDE-AD study (sabirnetug, early Alzheimer's) due late 2026.
• Option to license two candidates from JCR EBD collaboration expected in Q2 2026.
• Targeting IND filing for EBD lead candidate in mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.